Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.

Hematology (Amsterdam, Netherlands) - 1 Feb 2009

Larsen Thomas Stauffer, Pallisgaard Niels, de Stricker Karin, Møller Michael Boe, Hasselbalch Hans Carl

Abstract excerpt

Besides being an invaluable marker of clonal disease in chronic myeloproliferative disorders (CMPDs), the JAK2 V617F mutation and the mutated allele burden have an impact on disease phenotype and may provide information on prognosis. Recently, hydroxyurea (HU) has been shown to induce a rapid decline in the JAK2 V617F allele burden. The aim of the present study was to assess the dynamics of the JAK2 V617F allele...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Chronic Disease
Share to Hydroxyurea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Platelet Aggregation Inhibitors

Share to Polymerase Chain Reaction

Share to Quinazolines

Source

Identifiers

PMID: 19154659
DOI: 10.1179/102453309X385188

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.PMID 19154659Read ↗

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.Semantic proximity Read ↗

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.Semantic proximity Read ↗

The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.Semantic proximity Read ↗

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.Semantic proximity Read ↗

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Semantic proximity Read ↗

JAK2V617F allele burden is associated with transformation to myelofibrosis.Semantic proximity Read ↗

Acquired DNA mutations associated with in vivo hydroxyurea exposureSemantic proximity Read ↗

Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.Semantic proximity Read ↗

JAK2 V617F allele burden quantified by real time quantitative polymerase chain reaction and competitive polymerase chain reaction in patients with chronic myeloproliferative neoplasia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.